India, Aug. 19 -- Enorama Pharma AB (publ) (ERMA.ST), a producer and supplier of oral nicotine products, reported interim financial results for the first half and second quarter of 2026.
The company sells its nicotine products under the NIC-S label, and previously received an acceptance letter for its Pre-Market Tobacco Product Application (PMTA) from the U.S. Food and Drug Administration (FDA).
Q2 Financial Results:
The company reported no revenue from net sales for the second quarter, while in the same period last year, sales amounted to SEK 0.73 million.
Operating losses were recorded at SEK 11.71 million, slightly lower that the SEK 15.32 million from a year ago.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189...